HIV-subtype A is associated with poorer neuropsychological performance compared with subtype D in antiretroviral therapy-naive Ugandan children

View/ Open
Date
2010Author
Boivin, Michael J.
Bangirana, Paul
Kamya, Moses R.
Achan, Jane
Akello, Carolyne
Wong, Joseph K.
Boal, Hannah E.
Ruel, Theodore D.
Havlir, Diane V.
Charlebois, Edwin
Eller, Leigh A.
Cao, Huyen
Metadata
Show full item recordAbstract
Background: HIV-subtype D is associated with more rapid disease progression and
higher rates of dementia in Ugandan adults compared with HIV-subtype A. There are no
data comparing neuropsychological function by HIV subtype in Ugandan children.
Design: One hundred and two HIV-infected antiretroviral therapy (ART) naive
Ugandan children 6–12 years old (mean 8.9) completed the Kaufman Assessment
Battery for Children, second edition (KABC-2), the Test of Variables of Attention (TOVA),
and the Bruininks–Oseretsky Test for Motor Proficiency, second edition (BOT-2). Using a
PCR-based multiregion assay with probe hybridization in five different regions (gag, pol,
vpu, env, gp-41), HIV subtype was defined by hybridization in env and by total using two
or more regions. Analysis of covariance was used for multivariate comparison.
Results: The env subtype was determined in 54 (37 A, 16 D, 1 C) children. Subtype A
andDgroups were comparable by demographics, CD4 status, andWHOstage. Subtype
A infections had higher log viral loads (median 5.0 vs. 4.6, P¼0.02). Children with A
performed more poorly than those with D on all measures, especially on KABC-2
Sequential Processing (memory) (P¼0.01), Simultaneous Processing (visual–spatial
analysis) (P¼0.005), Learning (P¼0.02), and TOVA visual attention (P¼0.04). When
adjusted for viral load, Sequential and Simultaneous Processing remained significantly
different. Results were similar comparing by total HIV subtype.
Conclusion: HIV subtype A children demonstrated poorer neurocognitive performance
than those with HIV subtype D. Subtype-specific neurocognitive deficits may reflect
age-related differences in the neuropathogenesis of HIV. This may have important
implications for when to initiate ART and the selection of drugs with greater central
nervous system penetration.